LIV Emles at Home ETF

Samaritan Pharmaceuticals Inc. (AMEX:LIV): -- PII/III HIV Oral Entry Inhibitor Drug -- Cardiovascular Drug SP-1000 -- Alzheimer's Drug SP-233 -- Alzheimer's Blood Diagnostic -- Breast Cancer Diagnostic -- Alzheimer's Animal Model Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today, it is taking the opportunity to present its pipeline of innovative drugs at Bio 2006 in Chicago April 9th thru April 12, 2006. Samaritan will seek to out-license its promising drugs and diagnostics; and at the same time focus on in-licensing opportunities. Samaritan has established its own marketing and sales arm in Europe, which focuses on in-licensing niche drugs from other pharmaceutical companies, to sell their products in Eastern Europe, creating a revenue source for Samaritan. BIO, the Biotechnology Industry Organization, is the industry's largest trade organization bringing together over 18 thousand people from around the world, representing every aspect of the biotech community. Dr. Greeson, CEO of Samaritan stated, "BIO is the best venue for us to discuss our out-licensing opportunities with key executives from major pharmaceuticals. Everyone in the partnering section of the conference focuses on deals, and we normally have every half hour time slot filled for the three days by the time we get there. In addition, this year a main priority for us is to in-license other company's drugs, to market in the mostly overlooked South East and Central Europe, mainly Greece, Bulgaria, Romania, Croatia, Serbia, Turkey, Slovenia, Slovakia, Czech Republic, Poland and Hungary." Samaritan Pharmaceuticals: "We LIV....to Save Lives." Samaritan is a small-cap Biotech, driven to discover, develop, and commercialize, innovative therapeutics' for AIDS, Alzheimer's, Cancer and Heart disease. Look at www.samaritanpharma.com. Please register on Website so we can notify you of upcoming conference calls, news and events. Disclaimer The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.